Determination of Human Effective Dose via Translational Ocular Modeling: Clinical Translation of a Novel Topical Agent Using PBPK
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70717 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Woojin Jung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Clinical Pharmacy, CHA University, Pocheon, Republic of Korea. Hauptthemen laut MEDLINE: Models, Biological, Macular Degeneration, Ophthalmic Solutions. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Government, Core Technology Development Project for Environmental Diseases Prevention and Management, Korea Ministry of Environment (MOE).
Abstract (Originalsprache)
Wet age‐related macular degeneration (wAMD) is a leading cause of vision loss, and human dose selection for ocular therapeutics remains a key translational challenge. We developed a physiologically based pharmacokinetic (PBPK) model for EB‐203 to guide dose selection by translating preclinical ocular tissue exposure to human. PK data were obtained from mouse and rabbit studies and human plasma PK from a phase I trial. The model incorporated species‐specific ocular physiology, drug permeability, and pharmacokinetics, and was implemented using an open‐source PBPK modeling software (MoBi, version 12.2, Open Systems Pharmacology). Drug‐specific model parameters were estimated using mouse and rabbit plasma and ocular tissue concentration data. Human plasma PK data from a Phase I clinical trial were then used to estimate human‐specific systemic clearance, and human ocular tissue concentrations were subsequently predicted by the model. Simulated human retinal drug concentrations (AUC, C max , and C avr ) under multiple dosing regimens were evaluated against preclinical efficacy thresholds to determine the optimal dosing strategy. The model adequately described drug disposition across species, with most predicted PK parameters falling within a 2‐fold error of the observed data. Simulations suggested that a 4% four‐times‐daily dosing regimen in humans achieves retinal exposure comparable to the efficacious mouse concentrations. No significant systemic accumulation was observed, indicating a favorable safety profile. This PBPK framework provides a practical approach for predicting human ocular drug exposure and can be adapted to other compounds or ocular indications in the absence of direct tissue sampling. These results support further clinical evaluation of EB‐203 for the treatment of wAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Clinical Pharmacy, CHA University, Pocheon, Republic of Korea.
- EyeBioKorea Inc., Busan, Republic of Korea.
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae-si, Gyeongsangnam-do, Republic of Korea.
- College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
- Senior Health Convergence Research Center, Chungnam National University, Daejeon, Republic of Korea.
- Department of Bio-AI Convergence, Chungnam National University, Daejeon, Republic of Korea.
ORCID-Profile: Woojin Jung, Hwi-Yeol Yun, Soyoung Lee, Jaewook Yang, Jung-Woo Chae
Förderung
- Korea Government
- Core Technology Development Project for Environmental Diseases Prevention and Management
- Korea Ministry of Environment (MOE)
- Korea Machine Learning Ledger Orchestration for Drug Discovery Project (K-MELLODDY)
- Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea
- Korea Institute of Toxicology (KIT) Research Program
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Jung, W., Lee, J. J., Cho, Y., Min, K. A., Yun, H. Y., Lee, S., Yang, J., & Chae, J. W. (2026). Determination of Human Effective Dose via Translational Ocular Modeling: Clinical Translation of a Novel Topical Agent Using PBPK. Clinical and Translational Science. https://doi.org/10.1111/cts.70717
Vancouver
Jung W, Lee JJ, Cho Y, Min KA, Yun HY, Lee S, et al. Determination of Human Effective Dose via Translational Ocular Modeling: Clinical Translation of a Novel Topical Agent Using PBPK. Clinical and Translational Science. 2026. doi:10.1111/cts.70717
BibTeX
@article{Jung2026,
author = {Jung, Woojin and Lee, Jamie Jaeheung and Cho, Yunseok and Min, Kyoung Ah and Yun, Hwi-Yeol and Lee, Soyoung and Yang, Jaewook and Chae, Jung-Woo},
title = {Determination of Human Effective Dose via Translational Ocular Modeling: Clinical Translation of a Novel Topical Agent Using PBPK},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70717}
}
EUVIMED